Human Metapneumovirus Diagnostics Market Report 2026

The human metapneumovirus diagnostics market size has grown rapidly in recent years. It will grow from $0.54 billion in 2025 to $0.59 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising incidence of respiratory tract infections, increased hospitalization of infants and elderly patients, expansion of pcr-based diagnostic capabilities, growing awareness of non-influenza respiratory viruses, improved access to diagnostic laboratories.

The human metapneumovirus diagnostics market size is expected to see strong growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing demand for rapid respiratory diagnostics, expansion of multiplex and syndromic testing, growing investments in molecular diagnostic technologies, rising focus on early and accurate viral detection, increasing preparedness for seasonal respiratory outbreaks. Major trends in the forecast period include increasing adoption of molecular diagnostics for respiratory viruses, rising demand for rapid and point-of-care hmpv testing, growing emphasis on early detection in pediatric and geriatric care, expansion of multiplex respiratory pathogen testing panels, increasing integration of diagnostic results with clinical decision-making.

The increasing prevalence of respiratory infections is expected to drive growth in the human metapneumovirus (hMPV) diagnostics market. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the sinuses, throat, airways, and lungs. Exposure to harmful pollutants can irritate and weaken the respiratory tract, making individuals more susceptible to infections. hMPV diagnostics help identify human metapneumovirus as the cause of respiratory illness, enabling accurate treatment and improved patient management. For example, in January 2025, the UK Health Security Agency reported that during the 2023-2024 season, respiratory infection rates in England peaked at 8 per 100,000 in weeks 50 and 52 of 2023 and increased to 10.2 per 100,000 in week 4 of 2024. Acute respiratory infection (ARI) incidents in closed settings totaled 2,051, with most cases reported in care homes and hospitals. This rising prevalence of respiratory infections is therefore driving the growth of the hMPV diagnostics market.

Leading companies in the hMPV diagnostics market are focusing on developing advanced solutions, such as respiratory polymerase chain reaction (PCR) diagnostic kits, to enhance molecular diagnostic capabilities for a broad range of respiratory pathogens. Respiratory PCR diagnostics are molecular testing methods that detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For instance, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a China-based molecular diagnostics company, launched a respiratory pathogen multiplex real-time PCR diagnostic kit. This solution can simultaneously detect multiple respiratory pathogens with high accuracy and rapid turnaround, improving diagnostic efficiency in both clinical and point-of-care settings. Its comprehensive coverage and precise performance support timely clinical decision-making, especially for respiratory infections with overlapping symptoms.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for an undisclosed amount. This acquisition strengthens AstraZeneca’s late-stage pipeline and expands its expertise in vaccines for high-burden respiratory diseases, particularly by advancing Icosavax’s lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and hMPV. Icosavax Inc., headquartered in the US, focuses on developing vaccines, particularly combination vaccines targeting respiratory viruses such as RSV and hMPV.

Major companies operating in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMérieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., Attogene.

North America was the largest region in the human metapneumovirus diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human metapneumovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the human metapneumovirus diagnostics market by increasing the cost of imported reagents, test kits, molecular diagnostic instruments, and laboratory consumables. These effects are most pronounced in pcr-based and advanced molecular diagnostics segments and in regions such as North America and Europe that depend on global diagnostics supply chains. Higher procurement costs may affect testing budgets and adoption rates; however, tariffs are also encouraging local manufacturing of diagnostic kits, regional sourcing of reagents, and development of cost-effective rapid testing solutions, supporting long-term market resilience.

The human metapneumovirus diagnostics market research report is one of a series of new reports that provides human metapneumovirus diagnostics market statistics, including human metapneumovirus diagnostics industry global market size, regional shares, competitors with a human metapneumovirus diagnostics market share, detailed human metapneumovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. This human metapneumovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human metapneumovirus (hMPV) diagnostics refer to the techniques and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory tract infections, particularly in children, the elderly, and immunocompromised individuals.

The main product types in hMPV diagnostics include reagents and kits, as well as instruments. Reagents and kits are essential laboratory materials containing chemicals and tools designed to perform specific diagnostic tests or experiments. The diagnostic tests include molecular diagnostics, immunodiagnostics, culture-based methods, and others, employing technologies such as PCR-based assays, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and more. These diagnostics are used across various end-use settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.